lication No.	Applicant(s)
752.650	DICKSTEIN ET AL.
	Art Unit
Kesack	3691
on the cover sheet with the corresponding to the cover sheet with the corresponding to the REMAINS) CLOSED in this applies to the appropriate communication in the subject to the subject	plication. If not included will be mailed in due course. THIS o withdrawal from issue at the initiative national stage application from the complying with the requirements. SS AMENDMENT or NOTICE OF ation is deficient.
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).	
BIÓLOGICAL MATERIAL	must be submitted. Note the
5. Notice of Informal F 6. Interview Summary Paper No./Mail Da 7. Examiner's Amend 8. Examiner's Statem 9. Other	(PTO-413),
	S. This application is subject to MPEP 1308. 108,109 and 112-130. So U.S.C. § 119(a)-(d) or (f). In received. In received in Application No Ints have been received in this application. Note the attached EXAMINER ason(s) why the oath or declarate submitted. Patent Drawing Review (PTO endment / Comment or in the (a) should be written on the drawing ader according to 37 CFR 1.1216 f BIOLOGICAL MATERIAL THE DEPOSIT OF BIOLOGICAL THE DEPOSIT OF BIOLOGICAL THE DEPOSIT OF BIOLOGICAL Submitted and the comment of the comme

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set 1. forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 29, 2006 has been entered.

Allowable Subject Matter

- 2. Claims 79-84, 87-90, 95-97, 99-102, 104, 106, 108, 109, 112-130 are allowed.
- The following is an examiner's statement of reasons for allowance: See 3. Applicant's arguments, filed April 30, 2007, especially page 13, paragraphs 1 and 2, and page 14 paragraphs 1 and 2.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dan Kesack whose telephone number is 571-272-5882. The examiner can normally be reached on M-F, 9:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Alexander Kalinowski can be reached on 571-272-6771. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3691

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Respectfully Submitted,

Daniel Kesack Art Unit 3691 October 1, 2007

HANI M. KAZIMI PRIMARY EXAMINER